Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study checks if HS patients in saudi arabia like their new medication

NCT ID NCT06785779

Recruiting now Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 18 times

Summary

This study looks at how satisfied people with moderate to severe hidradenitis suppurativa (HS) are after starting a medication called secukinumab (Cosentyx). Researchers will ask about 77 adults in Saudi Arabia about their treatment experience and quality of life over 24 weeks. The goal is to see if the treatment is convenient, feels safe, and works well from the patient's point of view.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (HS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Riyadh, SAU, 11525, Saudi Arabia

  • Novartis Investigative Site

    RECRUITING

    Jeddah, 21391, Saudi Arabia

  • Novartis Investigative Site

    RECRUITING

    Jeddah, 23311, Saudi Arabia

  • Novartis Investigative Site

    RECRUITING

    Riyadh, 11211, Saudi Arabia

Conditions

Explore the condition pages connected to this study.

HIDRADENITIS SUPPURATIVA (HS)